Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

ABSTRACT:

Purpose

Numerous preclinical studies have demonstrated that angiogenesis inhibitors can increase the efficacy of radiotherapy (RT). We sought to examine the safety and efficacy of bevacizumab (BV) and RT in soft tissue sarcomas and explore biomarkers to help determine the treatment response.

Methods and materials

Patients with ≥5 cm, intermediate- or high-grade soft tissue sarcomas at significant risk of local recurrence received neoadjuvant BV alone followed by BV plus RT before surgical resection. Correlative science studies included analysis of the serial blood and tumor samples and serial perfusion computed tomography scans.

Results

The 20 patients had a median tumor size of 8.25 cm, with 13 extremity, 1 trunk, and 6 retroperitoneal/pelvis tumors. The neoadjuvant

SUBMITTER: Yoon SS 

PROVIDER: S-EPMC3021107 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature